DOD Biotech Public Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, sales was THB 293.22 million compared to THB 294.49 million a year ago. Revenue was THB 313.63 million compared to THB 298.19 million a year ago. Net loss was THB 12.12 million compared to THB 26.43 million a year ago. Basic loss per share from continuing operations was THB 0.014 compared to basic earnings per share from continuing operations of THB 0.023 a year ago. Diluted loss per share from continuing operations was THB 0.014 compared to diluted earnings per share from continuing operations of THB 0.023 a year ago. Basic loss per share was THB 0.029 compared to THB 0.064 a year ago. Diluted loss per share was THB 0.029 compared to THB 0.064 a year ago.